Cancer revolution is possible with more flexible FDA

Published



Last week, at a meeting of the American Society of Clinical Oncology, ASCO President George Sledge painted a hopeful, but also challenging, picture about new genomic technologies for fighting cancer. These technologies can unravel the genetic mechanisms driving the disease and point the way to new strategies to overcome cancer-drug resistance.

Sledge’s enthusiasm was balanced by realism: Revolutionary progress against cancer will depend not so much on the technology we use, as on our ability to rethink old paradigms for drug development and Food and Drug Administration drug approval.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.